


# HANDBOOK *of* RETINAL OCT

**S. DUKER**  
**M. A. K. WAHEED**  
**DARIN R. GOLDMAN**

**ELSEVIER**  
SAUNDERS

# HANDBOOK *of* RETINAL OCT

## Lead Editor

---

### **Jay S. Duker MD**

Director, New England Eye Center  
Professor and Chairman,  
Department of Ophthalmology  
Tufts Medical Center  
Tufts University School of Medicine  
Boston, MA, USA

## Associate Editors

---

### **Nadia K. Waheed MD MPH**


Assistant Professor of Ophthalmology  
New England Eye Center  
Tufts Medical Center  
Tufts University School of Medicine  
Boston, MA, USA

### **Darin R. Goldman MD**

Vitreoretinal Surgeon  
Retina Group of Florida  
Fort Lauderdale, FL, USA

For additional online content visit

**expertconsult**



London, New York, Oxford, Philadelphia, St Louis, Sydney, Toronto

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

### Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

With respect to any drug or pharmaceutical products identified, readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of practitioners, relying on their own experience and knowledge of their patients, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

**ISBN:** 978-0-323-18884-5

**e-book ISBN:** 978-0-323-18885-2

**ELSEVIER**

your source for books,  
journals and multimedia  
in the health sciences

[www.elsevierhealth.com](http://www.elsevierhealth.com)



Working together  
to grow libraries in  
developing countries

[www.elsevier.com](http://www.elsevier.com) • [www.bookaid.org](http://www.bookaid.org)

The  
publisher's  
policy is to use  
paper manufactured  
from sustainable forests

*Don't Forget Your Online Access to*

**ExpertConsult.com**

## ***Mobile. Searchable. Expandable.***

**ACCESS** it on any Internet-ready device

**SEARCH** all Expert Consult titles you own

**LINK** to PubMed abstracts

### **ALREADY REGISTERED?**

1. Log in at expertconsult.com
2. Scratch off your Activation Code below
3. Enter it into the "Add a Title" box
4. Click "Activate Now"
5. Click the title under "My Titles"

### **FIRST-TIME USER?**

#### **1. REGISTER**

- Click "Register Now" at expertconsult.com
- Fill in your user information and click "Continue"

#### **2. ACTIVATE YOUR BOOK**

- Scratch off your Activation Code below
- Enter it into the "Enter Activation Code" box
- Click "Activate Now"
- Click the title under "My Titles"

For technical assistance:  
email [online.help@elsevier.com](mailto:online.help@elsevier.com)  
call 800-401-9962 (inside the US)  
call +1-314-995-3200 (outside the US)

**Duker  
Scratch Gently  
to Reveal Code**



# **ExpertConsult.com**

# HANDBOOK *of* RETINAL **OCT**

DCR21/02

## Preface

Optical coherence tomography (OCT) was 'discovered' in an optics lab at the Massachusetts Institute of Technology in the late 1980s by James Fujimoto and his collaborators: Carmen Puliafito, Joel Schuman, David Huang, Eric Swanson and Mike Hee. It began as an effort to experimentally measure excimer laser corneal ablation in real time. While it failed in that regard, the founders quickly identified the possibility that OCT could be employed to measure static ocular tissue thickness in real time. The first publication on OCT was in *Science* in 1991 and by 1996 the technology was transferred to a commercial company and soon thereafter commercial devices began to be sold.

In 2013, it is safe to say that OCT is one of the most important ancillary tests in ophthalmology and it is indisputably THE most important ancillary test in the subspecialty of the retina. We set out to produce an easy-to-read, brief but complete handbook of OCT images that was disease-based. Given the importance of OCT in our practices, we concluded that the OCT images should be the major focus of the book. Consistency of chapter layout, excellent images, and well-documented pathologic features were all goals. This book has minimal clinical description of the pathologic entities. There are plenty of excellent textbooks that cover these entities in more depth. We hope you find this handbook useful in your clinical practice on a daily basis.

## List of Contributors

**Daniela Ferrara MD PhD**

Researcher  
New England Eye Center  
Tufts University School of Medicine  
Boston, MA, USA

**Alexandre S.C. Reis MD**

Department of Ophthalmology  
University of São Paulo  
São Paulo, SP, Brazil

**Sana Nadeem MBBS FCPS**

Senior Registrar  
Ophthalmology Department  
Fauji Foundation Hospital  
Rawalpindi, Pakistan

## Acknowledgements

The development of optical coherence tomography and its emergence as the most important ancillary test in ophthalmology is inextricably linked to the New England Eye Center at Tufts Medical Center and its physicians. The clinical experiences summarized in this book are based on the collective expertise gained at the Eye Center over the past two decades and we are very grateful to our colleagues Caroline Bauman, Elias Reichel, Chris Robinson, Adam Rogers and Andre Witkin, with whom we are privileged to share patients and who have been an inexhaustible resource for this endeavor. We would also like to acknowledge the unparalleled ophthalmic imaging department at the New England Eye Center whose members acquired most of the images included in this book. Thanks also go out to the contributing authors and to our production team at Elsevier who worked on a very tight schedule to get the book published in just over six months. Our fellows and residents, whose questions provide constant intellectual challenge, also deserve acknowledgement. And last but perhaps most importantly, we would like to thank our families for their patience and support.

## Dedications

To my wife Julie and my children, Jake, Bear, Sam and Elly whose support, love, patience and understanding allow me to pursue projects like this book. Also, to Carmen Puliafito, Joel Schuman and Jim Fujimoto – without them OCT would not exist and without their mentorship and collaboration I would never have been immersed in it.

*Jay S. Duker*

To Khadija and Ahmed, for their patience, generosity and encouragement. To my mother, the constant inspiration, without whom none of this would be possible. To my mentors past and present, and to my co-authors who made the process of writing this book such a phenomenally enjoyable and educational experience.

*Nadia K. Waheed*

To my wife Robin, whose constant love and encouragement allow me to pursue my passions, and to my parents Marisse and Tony and sister Candice, whose support I am forever grateful to have.

*Darin Goldman*



**AMD** age-related macular degeneration  
**ARN** acute retinal necrosis

**BM** Bruch's membrane  
**BRAO** branch retinal artery occlusion  
**BRVO** branch retinal vein occlusion

**CiRAO** cilioretinal artery occlusion  
**CME** cystoid macular edema  
**CNV** choroidal neovascularization  
**CRAO** central retinal artery occlusion  
**CRVO** central retinal vein occlusion  
**CSCR** central serous chorioretinopathy  
**CWS** cotton wool spots

**DME** diabetic macular edema  
**DR** diabetic retinopathy

**EDI** enhanced depth imaging  
**ELM** external limiting membrane  
**ERM** epiretinal membrane  
**ETDRS** Early Treatment of Diabetic Retinopathy Study

**FA** fluorescein angiography  
**FAF** fundus autofluorescence  
**FD** Fourier domain  
**FTMH** full-thickness macular hole

**GA** geographic atrophy  
**GCC** ganglion cell complex

**HE** hard exudates  
**HRVO** hemiretinal vein occlusion

**ICGA** indocyanine green angiography  
**ICP** intracranial pressure  
**ILM** internal limiting membrane  
**INL** inner nuclear layer  
**IPL** inner plexiform layer  
**IRF** intraretinal fluid

**IRMA** intraretinal microvascular abnormalities

**IS** inner segment of photoreceptors  
**IS-OS** inner segment – outer segment (of photoreceptors)

**LE** left eye  
**LMH** lamellar macular hole

**MacTel** macular telangiectasia  
**MCP** multifocal choroiditis with panuveitis

**NFL** nerve fiber layer  
**NPDR** non-proliferative diabetic retinopathy  
**NVD** neovascularization of the disc  
**NVE** neovascularization elsewhere (retinal neovascularization)  
**NVI** neovascularization of the iris

**OCT** optical coherence tomography  
**ONH** optic nerve head  
**ONL** outer nuclear layer  
**OPL** outer plexiform layer  
**OS** outer segment of photoreceptors

**PCME** postoperative cystoid macular edema  
**PCV** polypoidal choroidal vasculopathy  
**PDR** proliferative diabetic retinopathy  
**PED** pigment epithelial detachment  
**PFC** perfluorocarbon  
**PVD** posterior vitreous detachment

**RAP** retinal angiomatous proliferation  
**RCH** retinal capillary hemangioma  
**RD** retinal detachment  
**RE** right eye  
**RNFL** retinal nerve fiber layer  
**RP** retinitis pigmentosa  
**RPE** retinal pigment epithelium

- RRD** rhegmatogenous retinal detachment
- RS** retinoschisis
- SD** spectral domain
- SD-OCT** spectral domain optical coherence tomography
- SRF** subretinal fluid
- SS** swept source
- SVP** summed voxel projection
- TD** time domain
- TD-OCT** time domain optical coherence tomography
- TRD** tractional retinal detachment
- TSINT** temporal, superior, inferior, nasal temporal scan pattern
- VEGF** vascular endothelial growth factor
- VKH** Vogt-Koyanagi-Harada
- VMA** vitreomacular adhesion
- VMT** vitreomacular traction
- VRL** vitreoretinal lymphoma
- XLRS** X-linked juvenile retinoschisis

Preface .....	viii
List of Contributors.....	ix
Acknowledgements.....	x
Dedications .....	x
Glossary .....	xi

## Part 1: Introduction to OCT..... 1

Section 1: OCT: What It Is .....	2
Chapter 1.1 Scanning Principles .....	2
Chapter 1.2 Basic Scan Patterns and OCT Output.....	4
Section 2: OCT Interpretation.....	8
Chapter 2.1 OCT Interpretation .....	8
Section 3: OCT Artifacts .....	10
Chapter 3.1 Artifacts on OCT.....	10
Section 4: Normal Retinal Anatomy and Basic Pathologic Appearances.....	14
Chapter 4.1 Normal Retinal Anatomy and Basic Pathologic Appearances .....	14

## Part 2: Optic Nerve Disorders..... 23

Section 5: Interpretation of Optic Nerve OCTs .....	24
Chapter 5.1 Basic Optic Nerve Scan Patterns and Output .....	24
Daniela Ferrara	
Section 6: Optic Nerve Disorders.....	28
Chapter 6.1 Glaucoma .....	28
Daniela Ferrara and Alexandre S.C. Reis	
Chapter 6.2 Optic Neuropathies and Papilledema.....	30
Daniela Ferrara and Alexandre S.C. Reis	
Chapter 6.3 Congenital Optic Nerve Head Abnormalities .....	32
Daniela Ferrara and Alexandre S.C. Reis	

## Part 3: Macular Disorders ..... 35

Section 7: Dry Age-Related Macular Degeneration .....	36
Chapter 7.1 Dry Age-Related Macular Degeneration.....	36
Section 8: Wet Age-Related Macular Degeneration .....	38
Chapter 8.1 Wet Age-Related Macular Degeneration.....	38
Section 9: Macular Pathology Associated with Myopia .....	46
Chapter 9.1 Posterior Staphyloma .....	46
Chapter 9.2 Myopic Choroidal Neovascular Membrane .....	48
Chapter 9.3 Myopic Macular Schisis .....	50
Chapter 9.4 Dome-Shaped Macula.....	52
Chapter 9.5 Myopic Tractional Retinal Detachment.....	53

<b>Section 10: Vitreomacular Interface Disorders</b>	54
Chapter 10.1 Vitreomacular Adhesion and Vitreomacular Traction	54
Chapter 10.2 Full-Thickness Macular Hole	56
Chapter 10.3 Epiretinal Membrane	58
<b>Section 11: Miscellaneous Causes of Macular Edema</b>	60
Chapter 11.1 Postoperative Cystoid Macular Edema	60
Chapter 11.2 Macular Telangiectasia	62
Chapter 11.3 Uveitis	68
<b>Section 12: Miscellaneous Macular Disorders</b>	70
Chapter 12.1 Central Serous Chorioretinopathy	70
Chapter 12.2 Hydroxychloroquine Toxicity	72
Chapter 12.3 Pattern Dystrophy	74
Chapter 12.4 Oculocutaneous Albinism	76
Chapter 12.5 Subretinal Perfluorocarbon	78
Chapter 12.6 X-Linked Juvenile Retinoschisis	80
<b>Part 4: Retinal Vascular Disorders</b>	83
<b>Section 13: Diabetic Retinopathy</b>	84
Chapter 13.1 Non-Proliferative Diabetic Retinopathy	84
Chapter 13.2 Diabetic Macular Edema	88
Chapter 13.3 Proliferative Diabetic Retinopathy	90
<b>Section 14: Retinal Vein Occlusion</b>	92
Chapter 14.1 Branch Retinal Vein Occlusion	92
Chapter 14.2 Central Retinal Vein Occlusion	94
<b>Section 15: Retinal Artery Occlusion</b>	96
Chapter 15.1 Branch Retinal Artery Occlusion	96
Chapter 15.2 Central Retinal Artery Occlusion	98
Chapter 15.3 Cilioretinal Artery Occlusion	100
<b>Part 5: Inherited Retinal Degenerations</b>	103
<b>Section 16: Inherited Retinal Degenerations</b>	104
Chapter 16.1 Retinitis Pigmentosa	104
Chapter 16.2 Stargardt Disease	106
Chapter 16.3 Best Disease	108
Chapter 16.4 Cone Dystrophy	110
<b>Part 6: Uveitis And Inflammatory Diseases</b>	113
<b>Section 17: Posterior Non-Infectious Uveitis</b>	114
Chapter 17.1 Multifocal Choroiditis	114
Sana Nadeem	
Chapter 17.2 Birdshot Chorioretinopathy	116
Sana Nadeem	
Chapter 17.3 Serpiginous Choroiditis	118
Sana Nadeem	
Chapter 17.4 Vogt-Koyanagi-Harada Disease	120
Sana Nadeem	
Chapter 17.5 Sympathetic Ophthalmia	122
Sana Nadeem	
Chapter 17.6 Posterior Scleritis	124
Sana Nadeem	

<b>Section 18: Posterior Infectious Uveitis</b> .....	126
Chapter 18.1 <i>Toxoplasma Chorioretinitis</i> .....	126
Chapter 18.2 <i>Tuberculosis</i> .....	128
Chapter 18.3 <i>Acute Syphilitic Posterior Placoid</i> <i>Chorioretinitis</i> .....	130
Chapter 18.4 <i>Candida Albicans Endogenous</i> <i>Endophthalmitis</i> .....	132
Chapter 18.5 <i>Acute Retinal Necrosis Syndrome</i> .....	134

## **Part 7: Trauma**..... 137

<b>Section 19: Physical Trauma</b> .....	138
Chapter 19.1 <i>Commotio Retinae</i> .....	138
Chapter 19.2 <i>Choroidal Rupture and Subretinal Hemorrhage</i> ....	140
Chapter 19.3 <i>Valsalva Retinopathy</i> .....	142
<b>Section 20: Photothermal, Photomechanical, and Photochemical</b> <b>Trauma</b> .....	144
Chapter 20.1 <i>Laser Injury (Photothermal and</i> <i>Photomechanical)</i> .....	144
Chapter 20.2 <i>Retinal Light Toxicity (Photochemical)</i> .....	146

## **Part 8: Tumors**..... 149

<b>Section 21: Choroidal Tumors</b> .....	150
Chapter 21.1 <i>Choroidal Nevus</i> .....	150
Chapter 21.2 <i>Choroidal Melanoma</i> .....	152
Chapter 21.3 <i>Choroidal Hemangioma</i> .....	154
<b>Section 22: Retinal Tumors</b> .....	156
Chapter 22.1 <i>Retinal Capillary Hemangioma</i> .....	156
Chapter 22.2 <i>Retinoblastoma</i> .....	158
<b>Section 23: Other Tumors</b> .....	160
Chapter 23.1 <i>Metastatic Choroidal Tumor</i> .....	160
Chapter 23.2 <i>Vitreoretinal Lymphoma</i> .....	162

## **Part 9: Peripheral Retinal Abnormalities**..... 165

<b>Section 24: Retinal Detachment</b> .....	166
Chapter 24.1 <i>Retinal Detachment</i> .....	166
<b>Section 25: Retinoschisis</b> .....	168
Chapter 25.1 <i>Retinoschisis</i> .....	168
<b>Section 26: Lattice Degeneration</b> .....	170
Chapter 26.1 <i>Lattice Degeneration</i> .....	170

<b>Index</b> .....	173
--------------------	-----

# PART 1: Introduction to OCT

## **Section 1: OCT: What It Is ..... 2**

1.1 *Scanning Principles* ..... 2

1.2 *Basic Scan Patterns and OCT Output* ..... 4

## **Section 2: OCT Interpretation ..... 8**

2.1 *OCT Interpretation* ..... 8

## **Section 3: OCT Artifacts ..... 10**

3.1 *Artifacts on OCT* ..... 10

## **Section 4: Normal Retinal Anatomy and Basic Pathologic Appearances ..... 14**

4.1 *Normal Retinal Anatomy and Basic Pathologic  
Appearances* ..... 14

# 1.1

## Scanning Principles

Optical coherence tomography (OCT) is a medical diagnostic imaging technology that captures micron resolution three-dimensional images. It is based on the principle of optical reflectometry, which involves the measurement of light back-scattering through transparent or semi-transparent media such as biological tissues. It achieves this by measuring the intensity and the echo time delay of light that is scattered from the tissues of interest. Light from a broadband light source is broken into two arms, a reference arm and a sample arm that is reflected back from structures at various depths within the posterior pole of the eye.

There are two main ways in which the backscattered light can be detected:

- ▶ Time domain (TD) detection
- ▶ Fourier domain (FD) detection – which is further broken down into:
  - Spectral domain (SD)
  - Swept source (SS)

### Time Domain OCT

---

In time domain OCT scanning, light from the reference arm and light reflected back from the sample undergo interference, and the interference over time is used to generate an 'A-scan' depth resolved image of the retina at a single point. Moving the sample and the light source with respect to each other generates multiple A-scans that are combined into a cross-sectional linear image called the B-scan or 'line scan'. Scanning speeds of TD-OCTs are typically around 400 A-scans/second. The primary commercially available TD-OCT device is the Stratus OCT™ made by Carl Zeiss Meditech.

### Spectral Domain OCT

---

In this technology, the spectral interference pattern between the reference beam and the sample beam is dispersed by a spectrometer and collected simultaneously with an array detector. This simultaneous collection allows for much faster scanning speeds than the traditional time domain devices where a mechanically moving interferometer gathers the data over time. An A-scan is then generated using an inverse Fourier transform on the simultaneously gathered data. Commercially available SD-OCT devices have scanning rates of 18,000–70,000 A-scans/second.

Higher scan speeds in the SD-OCT faster acquisition time, which minimizes the chance of eye movements during acquisition, especially in patients with poor fixation. Both hardware and software enhancements permit precise image registration which allows for more reliable comparison between visits. Faster acquisition speeds also mean a higher sampling density of the macula, minimizing the chances of missing pathology. The higher speeds allow for the production of three-dimensional OCT scans. The broader light sources of SD-OCT devices achieve a higher axial resolution than TD-OCT, allowing better visualization of retinal anatomy. Commercially available SD-OCT devices include: the Cirrus OCT made by Carl Zeiss Meditech, the Spectralis OCT made by Heidelberg Engineering, 3D-OCT 1000 (Topcon), BiopTigen SD OCT (BiopTigen) and the RT-Vue (Optovue).

## Swept Source OCT

---

In swept source (or optical frequency domain) OCT scanning, the light source is rapidly swept in wavelength and the spectral interference pattern is detected on a single or small number of receivers as a function of time. The spectral interference patterns obtained as a function of time then undergo a reverse Fourier transform to generate an A-scan image. Higher scanning speeds allow for denser sampling and better registration. The swept source OCT also has less sensitivity roll-off with depth, allowing better visualization of structures deep to the retina. At present, swept source OCT is not widely available commercially with the DRI-OCT 1 (Topcon) being the only commercially available device.



# 1.2

## Basic Scan Patterns and OCT Output

Each commercially available OCT device has unique scan patterns that are programmed into the machine. There is considerable overlap between devices, however, with several general scan patterns available across all devices. The scan patterns for the major commercially available machines are summarized in Table 1.2.1. The two most commonly used scans in evaluating retinal disease are:

- ▶ Macular cube scan
- ▶ Line scan(s)

Depending on the particular machine, scan patterns may be programmable with respect to functions such as pixel density, B-scan density, speed, ability to oversample, and length of scanned image.

### Macular Cube Scan

---

Cube scans are 'volume' or '3D' scans analogous to computed tomography or magnetic resonance scans that acquire volumetric cubes of data. SD-OCT machines acquire a rapid series of line scans (B-scans), generally in a 6 mm × 6 mm square area centered on the fovea. The scans are generally at relatively lower resolution, in order to minimize the time of scanning. As a result, when examining individual line scans from a cube scan, some detail is lost. As a default the cube scan is centered at the fovea, but other areas of interest can be captured by manually centering the scan elsewhere in the retina. Optic nerve topographic scans are cube scans centered on the nerve.

In the Zeiss Cirrus SD-OCT, there are two macular cube scans available, with no ability to customize. Both scans capture a 6 mm × 6 mm area centered at the macula. There is a faster 200 × 200 cube (200 B-scans each comprised of 200 A-scans) or the slightly slower 512 × 128 cube (128 B-scans each comprised of 512 A-scans) that has higher quality horizontal scans. The 'volume scan' on the Heidelberg Spectralis uses a similar raster scanning protocol with a 'fast' 25 B-scans each consisting of 512 sample points or A-scans, or with a 'dense' 1024 × 49 default scanning protocol. The Topcon 3D OCT uses a 256 × 256 or a 512 × 128 scanning protocol. The RT-Vue '3D macular scan' consists of a 4 mm × 4 mm macular cube scan with 101 B-scans consisting of 512 A-scans each, and the MM5 protocol uses a mix of vertical and horizontal B-scans to create a grid-like (not true raster) scanning pattern.

- ▶ **Raster Scans:** raster scanning is one method used to obtain cube scans of the macula. This involves a systematic pattern of image capture over a rectangular area using closely spaced parallel lines. It leads to a uniform sampling density over the entire area being scanned with the OCT.
- ▶ **Radial Scans:** these consist of six to 12 high resolution line scans taken at radial orientations, all passing through the fovea. The RT-Vue's MM6 is a radial line scanning pattern with 12 lines radially oriented to the fovea, each 6 mm long. The macular radial scanning pattern of the Spectralis and the 6-line radial scan of the Topcon 3D OCT 100 are similar. A disadvantage of the radial line scans is that the machine interpolates between the scans when generating macular thickness maps. This is reasonable for the fovea where the lines are close to each other, but can miss lesions further out in the macula where the lines are spaced further apart.